Tang B, et al. - Via this meta-analysis of eight studies (n=9,254), researchers assessed the comparative risks of budesonide/formoterol vs placebo or monotherapies for the treatment of patients with stable COPD. Eligible studies included those with ≥ 12 weeks of follow-up. Upon review, findings were pooled using OR with corresponding 95% CI. The investigators found that, among patients with stable COPD, adverse events, including pneumonia and bronchitis, were not more common in those treated with combination therapy vs those who received control (placebo, formoterol, or budesonide) treatment. Findings also revealed higher risks of oral candidiasis and dysphonia among patients treated with combination therapy vs the non-inhaled corticosteroid group (placebo and formoterol).